MA50972A - Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide - Google Patents
Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamideInfo
- Publication number
- MA50972A MA50972A MA050972A MA50972A MA50972A MA 50972 A MA50972 A MA 50972A MA 050972 A MA050972 A MA 050972A MA 50972 A MA50972 A MA 50972A MA 50972 A MA50972 A MA 50972A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
- LSYANGLAZUZYFX-UHFFFAOYSA-N N-[1-[(5-cyanopyridin-2-yl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide Chemical compound C(#N)C=1C=CC(=NC=1)CN1N=C(C=C1)NC(CC1=CC=C(C=C1)C1(CC1)C(F)(F)F)=O LSYANGLAZUZYFX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50972A true MA50972A (fr) | 2020-10-14 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050972A MA50972A (fr) | 2017-07-05 | 2018-07-04 | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (fr) |
| EP (1) | EP3649117A1 (fr) |
| JP (2) | JP2020525475A (fr) |
| KR (1) | KR102645911B1 (fr) |
| CN (1) | CN110831932A (fr) |
| AU (1) | AU2018296423B2 (fr) |
| BR (1) | BR112020000099A2 (fr) |
| CA (1) | CA3067489A1 (fr) |
| CL (1) | CL2020000002A1 (fr) |
| EA (1) | EA202090193A1 (fr) |
| IL (1) | IL271764B2 (fr) |
| MA (1) | MA50972A (fr) |
| PH (1) | PH12020500040A1 (fr) |
| SG (1) | SG11201912881SA (fr) |
| UA (1) | UA126582C2 (fr) |
| WO (1) | WO2019008034A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3554490T3 (pl) | 2016-12-16 | 2022-05-30 | Idorsia Pharmaceuticals Ltd | Kombinacja farmaceutyczna zawierająca bloker kanału wapniowego typu T |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
| CA3161908A1 (fr) | 2019-12-20 | 2021-06-24 | Michael Ambuehl | Compositions pharmaceutiques comprenant du n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| WO2023240205A1 (fr) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Composés deutérés |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR100712A1 (es) * | 2014-06-03 | 2016-10-26 | Actelion Pharmaceuticals Ltd | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t |
| MX367519B (es) | 2014-09-15 | 2019-08-26 | Idorsia Pharmaceuticals Ltd | Compuestos triazolicos como bloqueadores de canales de calcio tipo t. |
| PL3554490T3 (pl) | 2016-12-16 | 2022-05-30 | Idorsia Pharmaceuticals Ltd | Kombinacja farmaceutyczna zawierająca bloker kanału wapniowego typu T |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active IP Right Grant
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/fr unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/fr active Pending
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 EP EP18749304.4A patent/EP3649117A1/fr active Pending
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020000099A2 (pt) | 2020-07-07 |
| EA202090193A1 (ru) | 2020-06-03 |
| EP3649117A1 (fr) | 2020-05-13 |
| KR20200018698A (ko) | 2020-02-19 |
| WO2019008034A1 (fr) | 2019-01-10 |
| IL271764B1 (en) | 2023-06-01 |
| CL2020000002A1 (es) | 2020-07-31 |
| US11555025B2 (en) | 2023-01-17 |
| US11059803B2 (en) | 2021-07-13 |
| PH12020500040A1 (en) | 2020-10-12 |
| AU2018296423B2 (en) | 2022-07-28 |
| IL271764A (en) | 2020-02-27 |
| KR102645911B1 (ko) | 2024-03-08 |
| US20210300894A1 (en) | 2021-09-30 |
| IL271764B2 (en) | 2023-10-01 |
| UA126582C2 (uk) | 2022-11-02 |
| JP2020525475A (ja) | 2020-08-27 |
| CA3067489A1 (fr) | 2019-01-10 |
| AU2018296423A1 (en) | 2020-02-20 |
| JP2023123679A (ja) | 2023-09-05 |
| US20200165221A1 (en) | 2020-05-28 |
| CN110831932A (zh) | 2020-02-21 |
| SG11201912881SA (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50972A (fr) | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide | |
| IL274488A (en) | Crystal forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| GB201609607D0 (en) | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts | |
| DK3259253T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| HK1259405A1 (zh) | N-[5-(3，5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氫吡喃-4-基氨基)-苯甲酰胺的新晶型 | |
| MA47596A (fr) | Formes cristallines du dérivé 4-pyrimidinesulfamide aprocitentan | |
| IL271726A (en) | Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2, 6-doxopyridin-3-yl)-1-oxoisoinodolin-5-yl)methyl)2-2-difluoroacetamide | |
| DK3154950T3 (da) | N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte | |
| ZA201804482B (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| DK3395342T3 (da) | Tablet omfattende 1-(3-(2-(1-benzothiophen-5-YL)ethoxy)propyl)azetidin-3-ol eller salt deraf | |
| HUE041725T2 (hu) | (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya | |
| GB2571937B (en) | Stable liquid suspension composition of fludrocortisone | |
| IL284509A (en) | Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide | |
| IT201600106806A1 (it) | Apparecchio di pulizia con elemento per l'isolamento acustico | |
| DK3908584T3 (da) | Krystalformer af 1-(1,2-dimethylpropyl)-n-ethyl-5-methyl-n-pyridazin-4-ylpyrazol-4-carboxamid | |
| SG11202103847QA (en) | Estimation of asymmetric aberrations | |
| SI3643704T1 (sl) | Novi intermediati za pripravo remifentanil hidroklorida | |
| IT201700050223A1 (it) | Procedimento per la preparazione di dexlansoprazolo cristallino | |
| IT201700025286A1 (it) | Forme cristalline di vinpocetina cloridrato | |
| GB201809911D0 (en) | Use of trpv1 agonists | |
| IT201700042701A1 (it) | Biophysis - composizione per ritardo di crescita intrauterino | |
| GB201621528D0 (en) | Use of trpv1 agonist |